Core Viewpoint - The "Annual Excellence in Innovation IPO" award recognizes companies that have demonstrated significant achievements in product, model, and organizational innovation over the past year, highlighting their ability to keep pace with market trends through continuous innovation [4]. Group 1: Award Recipients - Six companies were awarded the "Annual Excellence in Innovation IPO" award: MIRXES-B (02629.HK), Wuyi Vision (06651.HK), Yino Pharma (02591.HK), Yunhan Chip City (301563.SZ), Yunjing (02670.HK), and Yunzhisheng (09678.HK) [1]. - The ranking of the awarded companies is not in any specific order and is based on the first letter of their names [1]. Group 2: Evaluation Criteria - The evaluation for the award was based on quantitative data analysis and assessments from an expert review panel [4]. - The award aims to create a valuable reference list of listed companies and unicorns within the investment community, covering all companies listed on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4].

Core Viewpoint - The "Golden Award" annual excellence company selection by Gelonghui recognizes innovative companies in the IPO sector, highlighting their achievements in product, model, and organizational innovation over the past year [1][2]. Group 1: Award Winners - Six companies received the "Annual Excellence Innovation IPO" award: MIRXES-B (02629.HK), Wuyi Vision (06651.HK), Yinnuo Pharmaceutical-B (02591.HK), Yunhan Chip City (301563.SZ), Yunjin (02670.HK), and Yunzhisheng (09678.HK) [1]. - The ranking of the award winners is not in any particular order and is based on the first letter of the company names [1]. Group 2: Evaluation Criteria - The award evaluates companies based on quantitative data analysis and expert review, focusing on their innovation in products, business models, and organizational structures [1]. - The aim of the selection is to recognize new listed companies that have achieved excellent results through continuous innovation and alignment with market trends [1]. Group 3: Scope of the Selection - The "Golden Award" selection covers all listed companies and unicorns on major stock exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [2]. - The initiative is driven by the vision of providing valuable references for investors regarding listed companies and unicorns in the market [2].

人民财讯12月22日电，企查查APP显示，近日，云知声(安徽)智能科技有限公司成立，注册资本1000万 元，经营范围包含：人工智能基础软件开发；人工智能应用软件开发；人工智能基础资源与技术平台； 人工智能行业应用系统集成服务等。企查查股权穿透显示，该公司由云知声全资持股。 ...

2025年12月，在上海人工智能研究院打造的国内权威中文医疗大模型评测体系MedBench 4.0中，公司在 医疗智能体、大语言模型和多模态大模型中分别取得94.6分、65.7分、 59.6分的优异成绩，一举包揽了 医疗大模型全部三项技术範式第一，用实力打造行业标杆。而在国家人工智能应用中试基地(医疗)?浙 江发布的《MedAIBench测评榜(优秀国产医疗大模型)》中，公司医疗大模型凭借扎实的技术积累荣耀 登榜，彰显AI医疗垂域硬核实力。 智通财经APP讯，云知声(09678)发布公告，近日，公司发布医疗领域专家大模型"山海?知医大模型 5.0"版本("医疗大模型")，构建"医学文本大模型+医学多模态大模型"双核心产品体系，全面覆盖文本处 理、智能体协同、多模态感知等核心能力，整合医学知识问答、临床任务规划、影像解析等多元功能， 形成当前业界能力维度最丰富的医疗AI技术支撑体系之一。医疗大模型能够深度模拟临床思维进行复 杂推理，实现精准鉴别诊断与循证决策。公司依托海量优质医疗数据与专属知识库训练，在医学知识问 答、信息抽取等核心任务中达到业界顶尖水平;通过持续课程学习、知识图谱增强及循证对齐训练，最 大限度 ...

Core Insights - The company has launched the "Shanhai·Zhi Medical Model 5.0," a dual-core product system in the medical field, integrating a medical text model and a medical multimodal model, which covers core capabilities such as text processing, intelligent agent collaboration, and multimodal perception [1] - The medical model is designed to deeply simulate clinical thinking for complex reasoning, achieving precise diagnostic differentiation and evidence-based decision-making [1] Performance Metrics - In the MedBench 4.0 evaluation system, the company achieved scores of 94.6, 65.7, and 59.6 in medical intelligent agents, large language models, and multimodal models respectively, securing the top position in all three technical paradigms [2] - The company's medical model has been recognized in the MedAIBench evaluation list for excellent domestic medical models, showcasing its robust technical foundation [2] Application and Industry Impact - The medical model has been successfully implemented in numerous top-tier hospitals, demonstrating its clinical practical value and adaptability to industry standards and clinical needs [2] - The collaboration with top-tier hospitals for technical validation in high-demand clinical auxiliary diagnosis scenarios highlights the model's alignment with real-world medical requirements [2]

Core Insights - The company has launched the "Shan Hai Zhi Yi Model 5.0," a medical expert large model that integrates a dual-core product system of "medical text large model + medical multimodal large model," covering essential capabilities such as text processing, intelligent agent collaboration, and multimodal perception [1] - The medical large model simulates clinical thinking for complex reasoning, achieving precise differential diagnosis and evidence-based decision-making, supported by a vast amount of quality medical data and proprietary knowledge base [1] Performance Metrics - In the MedBench 4.0 evaluation system, the company achieved scores of 94.6, 65.7, and 59.6 in medical intelligent agents, large language models, and multimodal large models respectively, securing the top position in all three technical paradigms [2] - The company's medical large model has been successfully implemented in numerous top-tier hospitals, demonstrating its clinical practical value and adaptability to industry standards and clinical needs [2]

Core Insights - The company has launched a new medical large model version "Shanhai·Zhi Medical Model 5.0," which integrates a dual-core product system of "medical text large model + medical multimodal large model" to enhance capabilities in text processing, intelligent agent collaboration, and multimodal perception [1] - The medical large model is designed to simulate clinical thinking for complex reasoning, enabling precise diagnostic differentiation and evidence-based decision-making [1] - The company achieved top scores in the MedBench 4.0 evaluation system, securing first place in all three technical paradigms of medical large models, showcasing its industry-leading capabilities [2] Product and Technology - The medical large model encompasses diverse functions such as medical knowledge Q&A, clinical task planning, and image analysis, making it one of the most comprehensive medical AI technology support systems in the industry [1] - The model has been trained using vast amounts of high-quality medical data and proprietary knowledge bases, achieving industry-leading performance in core tasks like medical knowledge Q&A and information extraction [1] - Continuous learning, knowledge graph enhancement, and evidence alignment training are employed to minimize medical hallucinations, ensuring the authenticity and verifiability of the output [1] Market Application - The medical large model has been successfully implemented in numerous top-tier hospitals, demonstrating its practical value and adaptability to clinical requirements [2] - Collaborations with top-tier hospitals for technical validation in high-demand clinical auxiliary diagnosis scenarios highlight the model's alignment with industry standards and clinical needs [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 自願性公告 最新技術進展 本公告乃由雲知聲智能科技股份有限公司（「本公司」）自願作出，旨在知會本公司股東 及潛在投資者有關本公司的最新技術發展情況。 近日，本公司發佈醫療領域專家大模型「山海‧知醫大模型5.0」版本（「醫療大模型」）， 構建「醫學文本大模型+醫學多模態大模型」雙核心產品體系，全面覆蓋文本處理、智能 體協同、多模態感知等核心能力，整合醫學知識問答、臨床任務規劃、影像解析等多元 功能，形成當前業界能力維度最豐富的醫療AI技術支撐體系之一。醫療大模型能夠深度 模擬臨床思維進行複雜推理，實現精準鑒別診斷與循證決策。本公司依託海量優質醫療 數據與專屬知識庫訓練，在醫學知識問答、信息抽取等核心任務中達到業界頂尖水平； 通過持續課程學習、知識圖 ...

Core Insights - China is a significant market for global medical AI solutions, benefiting from technological advancements, high-quality medical data accumulation, supportive national policies, and growing market demand, leading to rapid growth in AI applications in healthcare [1][4]. Market Size and Growth - The market size for medical AI solutions in China is projected to grow from 9.1 billion yuan in 2021 to 16.4 billion yuan in 2024, with L1 solutions increasing from 5.8 billion yuan to 9.4 billion yuan, L2 solutions from 3.3 billion yuan to 6.9 billion yuan, and L3 solutions at 0.1 billion yuan [1][4]. - By 2025, the market size is expected to reach 18.2 billion yuan, with L1 solutions at 9.8 billion yuan, L2 solutions at 7.8 billion yuan, and L3 solutions at 0.6 billion yuan [1][4]. Industry Definition and Applications - Medical AI solutions utilize AI technologies such as machine learning, deep learning, natural language processing, and big data analysis to enhance various medical processes, including diagnosis, treatment, drug development, and hospital management [2][3]. - The industry is evolving from L1 and L2 solutions, which provide supportive insights, to L3 and L4 autonomous agents capable of executing tasks independently [2][3]. Industry Development Status - The integration of general large model capabilities with medical knowledge bases is driving the transition of medical AI solutions towards higher levels of autonomy [3][4]. - The global market for medical AI solutions is expected to grow from 23.2 billion yuan in 2021 to 40 billion yuan in 2024, with L1 solutions increasing from 13.9 billion yuan to 21.1 billion yuan, L2 solutions from 9.3 billion yuan to 18.7 billion yuan, and L3 solutions at 0.2 billion yuan [4]. Industry Chain - The medical AI solutions industry chain includes upstream data supply, hardware providers (chips, servers), cloud services, operating systems, and algorithms, with midstream companies providing AI solutions and downstream applications in healthcare institutions, pharmaceutical companies, and individual patients [5]. Policy Environment - The Chinese government has prioritized the application of AI in healthcare, implementing policies to support AI in medical diagnosis, health management, and insurance regulation, which are expected to accelerate the development of AI in healthcare [5]. Competitive Landscape - The industry features a competitive landscape with local giants, vertical startups, and multinational companies. Key players include iFlytek Medical, Baidu, United Imaging, CloudWalk, Weining Health, and Mindray Medical [7]. - iFlytek Medical is a leading company in the AI healthcare sector, leveraging its large model to empower various healthcare stakeholders and has developed comprehensive AI solutions for hospitals and primary care institutions [9][11]. Revenue Structure of Key Players - iFlytek Medical reported a revenue of 299 million yuan in the first half of 2025, with contributions from various solutions: 84 million yuan from primary care solutions, 58 million yuan from regional solutions, 53 million yuan from hospital solutions, and 104 million yuan from patient management services [11]. - The company aims to build a robust B-end ecosystem to strengthen its commercial channels [9]. Future Trends - The development of the medical AI industry will be driven by a combination of technology, data, scenarios, and regulation, leading to a more mature, deeper, and broader market landscape [12].

Core Viewpoint - The company, Yunzhisheng (09678), has announced the election of its third board of directors, which will take effect on December 10, 2025, following the approval of a temporary shareholders' meeting [1] Group 1: Board Composition - Dr. Liang Jiaen, Dr. Huang Wei, Dr. Kang Heng, and Dr. Li Xiaohan have been elected as executive directors of the third board [1] - Mr. Li Zhichao and Mr. Li Ang have been elected as non-executive directors [1] - Independent non-executive directors include Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua, and Dr. Zhang Kun [1] - The board will also include Dr. Liu Shengping, who was elected as a representative director at the 2025 employee representative assembly [1] Group 2: Leadership Appointments - Dr. Liang Jiaen has been elected as the chairman of the third board, with a term aligned with the board's three-year duration [1] - Dr. Huang Wei has been reappointed as the general manager of the company, with a term also aligned with the third board [1] Group 3: Departures - Dr. Li Peng, Mr. Kuang Ziping, Dr. Wang Cunfu, and Mr. Chen Hua have resigned from their positions as directors and related committee roles, effective December 10, 2025 [1]